Heart Failure
Conditions
Keywords
Heart Failure, Questionnaire, ECHO, Prospective
Brief summary
The AWARENESS HF-PD is a cross-sectional, multicenter, survey-based study. Cases who were admitted to the outpatient clinic and hospitalized with the diagnosis of Heart Failure (Acute and Chronic) will be included in the study.
Detailed description
Data entry personnel to be assigned at the centers throughout the study will apply a questionnaire consisting of different questions to patients referred to them by clinicians with the diagnosis of HF. In addition, clinical features of HF from the current file of the cases (NYHA, comorbid conditions, comorbid diseases, blood pressure, heart rate, latest biochemistry (BNP/NTproBNP if available), hematology test results, most recent ECG, most recent echocardiography , coronary angiography report, if any) will be recorded. No additional examination/procedure will be performed for the study, only the data of the examinations requested by the clinician in routine clinical practice will be entered. A total of 200 patients from 3 centers will be included in this study over a six-month period.
Interventions
OTHERQuestionnaires
Application of a study based questionnaire described in the protocol
Sponsors
Klinar CRO
AstraZeneca Turkey
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients aged 18 and over 2. Patients diagnosed with acute or chronic heart failure 3. Patients who agreed to participate in the study
Exclusion criteria
1. Patients who stated that they did not agree to participate in the study 2. Patients who were not diagnosed with Heart Failure or whose diagnosis was changed or not confirmed during the index application 3. Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Demographics | 6 months | At the end of the six-month recruitment period, demographic, symptoms, clinical follow-up status, d will be performed on all included patients. |
| Disease Information | 6 months | At the end of the six-month recruitment period disease information, treatment compliance, and awareness assessment will be performed on all included patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HF Percutaneous Intervention / Operation History (CRT, ICD, CRT-DI, Pacemaker, PKG, CABG and Heart Valve Operations) | 6 months | CRT, ICD, CRT-DI, Pacemaker, PKG, CABG and Heart Valve Operations |
| HF Comorbidities (CAD, AF, COPD, CRF, Anemia, Iron Defficiency, Hypo- Hypertiroidy, OSAS) | 6 months | (CAD, AF, COPD, CRF, Anemia, Iron Defficiency, Hypo- Hypertiroidy, OSAS |
| HF ECHO Results (EF, LA, SID, Mitral Defficiency, SPAB, DID, Septum, SEG Muscle Weakness, Trial Defficiency) | 6 Months | (EF, LA, SID, Mitral Defficiency, SPAB, DID, Septum, SEG Muscle Weakness, Trial Defficiency) |
| HF Laboratory Results (Glucose, BUN, Creatinine, GFR, Sodium, Potassium, Nt-ProBNP, ALT, AST, ALP, HS-CRP, cTN, Hemoglobine, WBC, Ferritine, TSAD, LDL, tryglyceride, ST3, GGT, INR, ST4) | 6 months | Glucose, BUN, Creatinine, GFR, Sodium, Potassium, Nt-ProBNP, ALT, AST, ALP, HS-CRP, cTN, Hemoglobine, WBC, Ferritine, TSAD, LDL, tryglyceride, ST3, GGT, INR, ST4) |
| HF Risk Factors (BMI, Diabetes, Hypertension, HLP, Tobbaco Use, CV Hereditary, Menapause, MI History and History of CMP in family) | 6 months | BMI, Diabetes, Hypertension, HLP, Tobbaco Use, CV Hereditary, Menapause, MI History and History of CMP in family |
Countries
Turkey (Türkiye)
Outcome results
None listed